MDA’s Scientific, Medical and Translational Research advisory committees comprise approximately 60 of the world’s leading researchers in the area of neuromuscular disease, who volunteer their expertise and diligence on behalf of those touched by the diseases in MDA’s program. Scientific Advisory Committee (SAC) members are experts primarily in fundamental aspects of neuromuscular disease, such as cell biology, genetics, biochemistry and neurophysiology. Most members of the Medical Advisory Committee (MAC) are physicians who specialize in treating patients with neuromuscular disease, and also lead research teams in the clinical aspects of neuromuscular disease. Translational Research Advisory Committee members are experts in drug development, coming from academia, industry and venture capital backgrounds. MDA also uses ad-hoc reviewers who are drawn from both basic and clinical sides of the spectrum, and review proposals relevant to their area of expertise when suitable committee members are not available. MDA also depends upon ad-hoc members for reviewing proposals submitted by SAC or MAC members, to prevent potential bias.
A single review takes hours of thoughtful work to complete. Reviewers must carve time from their packed schedules, after their own research, clinical, teaching and family duties are finished for the day. For this remarkable service, reviewers receive no compensation, other than the prestige of sitting on an MDA advisory committee and the satisfaction for advancing the neuromuscular disease field.
Learn more about MDA's funding review process.
Muscular Dystrophy Association — USA
222 S. Riverside Plaza, Suite 1500
Chicago, Illinois 60606
The Muscular Dystrophy Association (MDA) is a qualified 501(c)(3) tax-exempt organization.
©2015, Muscular Dystrophy Association Inc. All rights reserved.